Loading…

Alector, Inc.ALECCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum leader 91
Mkt cap
$383M
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$4.62M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.0%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$2.57
1D+0.4%
1W-2.3%
1M+30.5%
3M+13.7%
6M+21.2%
YTD+64.7%
1Y+107.3%
ATR %8.3%
Beta1.64
52w lowhigh9.5% off high

What Alector does

Employees: 103

Alector at a glance

Size Alector (ALEC) is a United States Health Care company (Biotechnology) with a market value of $383M, the 2864th largest of 3,085 United States companies the cockpit tracks. Shares closed at $2.57 on 18 Nov 2026.

Performance Over six months the shares gained 21.2%, against -31.0% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.

Growth Revenue grew 151.2% over the last twelve months (peer median +5.5%); the operating margin is 24.6% (peer median -4.3%).

Valuation It trades at 1.5× enterprise value to sales against a peer median of 5.2× (3rd cheapest of 16).

Short interest Short interest is 5.6% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026ALEC 116Peer median 69
Six months, rebased to 100: Alector against the median of its 20 peers (local-currency closes).

Alector financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$173M$21.0M$101M$97.1M$134M
Revenue growth—-79%+4%-27%—
Gross profit$165M$11.4M$91.7M$88.2M$125M
EBITDA$51.1M-$136M-$134M-$143M-$129M
Net income$41.4M-$143M-$119M-$130M-$133M
Free cash flow-$150M-$184M-$231M-$187M-$24.4M
Capital expenditure$149,000$41,000$1.25M$2.38M$4.12M
Total debt$21.0M$36.2M$42.5M$38.9M$43.3M

Quarterly statements and history in the cockpit →

Alector competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-40%-20%0%+20%300966PRTCPNV688687300683300381476060688098CTNM1167CRMD33786998688238EPRX688163456160CADL476830ALEC6-month return →1-month return →
Up and to the right = strong over both horizons. Alector is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×500×300966PRTC47606011676998456160476830ALECRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alector is the large dot.

Alector competitors and peer comparison

How Alector compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alector against its 20 peers (data as of 18 Nov 2026)
MeasureALECPeer medianRank in peer set
1-month return+30.5%-13.7%highest of 21
6-month return+21.2%-31.0%highest of 21
Distance from 52-week high-9.5%-47.6%highest of 21
Revenue growth (TTM)+151.2%+5.5%4th highest of 16
Operating margin24.6%-4.3%5th highest of 16
EV / Sales1.5×5.2×3rd cheapest of 16
EV / EBITDA5.2×20.7×3rd cheapest of 6
Net debt / EBITDA-2.3×-2.6×3rd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Alector ALECUnited States$383M+21%+151%25%1.5×n/an/a
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a
PureTech Health PRTC.LUnited Kingdom$378M-15%-4%-1,617%27.4×n/an/a
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a

Questions

Which companies are Alector's closest peers?
The cockpit's peer set: Hubei Goto Biopharm (300966.SZ), PureTech Health (PRTC.L), Polynovo (PNV.AX), Beijing Kawin Technology Share-Holding (688687.SS), Wuhan Hiteck Biological Pharma (300683.SZ), Guangdong Vtr Bio-Tech (300381.SZ), Beijing Luzhu Biotechnology (2480.HK), Onconic Therapeutics (476060.KS).
Is Alector expensive compared with its peers?
On ev / sales it trades at 1.5× against a peer median of 5.2×, 3rd cheapest of 16 in its peer set.
How has Alector stock performed?
Over six months to 18 Nov 2026 the shares returned +21.2% against -31.0% for the median peer; over one year +107.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.